CRL · Q3 2025 Earnings

Cautious

Charles River Laboratories

Reported November 5, 2025

30-second summary

30-second take: Revenue of $1.00B (-0.5% YoY, -1.6% organic) and non-GAAP EPS of $2.43 came alongside a tightened FY2025 outlook — EPS raised to $10.10–$10.30 (top of prior range) and organic revenue range narrowed to -1.5% to -2.5%. The operationally significant news is qualitative: management announced divestiture of ~7% of revenue, layered on $225M+ annualized cost savings, and explicitly stated DSA demand has "stabilized" with proposal activity up high single-digit. But Manufacturing was lowered from "essentially flat" to "flat to slightly lower," and management repeatedly refused to commit to 2026 DSA growth despite the recovery framing.

Headline numbers

EPS

Q3 FY2025

$2.43

Revenue

Q3 FY2025

$1.00B

-0.5% YoY

Operating margin

Q3 FY2025

13.3%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.00B	-0.5%	$1.03B	-3.1%
EPS	$2.43	—	$3.12	-22.1%
Operating margin	13.3%	—	9.7%	+360bps

Guidance

FY2025 Non-GAAP EPS raised to $10.10–$10.30 (top of prior range); full-year organic revenue decline narrowed to -1.5% to -2.5%; Q4 expected to show sequential EPS decline and continued organic revenue headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Non-GAAP EPS	Q3 FY2025	not explicitly guided	2.43	in-line	Met

New guidance

Metric	Period	Guide	YoY
Reported Revenue Growth	Q4 FY2025	flat to low single-digit decline	—
Organic Revenue Growth	Q4 FY2025	low to mid-single-digit decline year over year	—
Non-GAAP EPS	Q4 FY2025	flat to 10% below Q3 level of $2.43	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Non-GAAP EPS	FY 2025	$9.90 – $10.30	$10.10 – $10.30	+$0.20 at low end	Raised
Reported Revenue Growth	FY 2025	(2.5)% to (0.5)%	(1.5)% to (0.5)%	+1.0pts at low end	Raised
Organic Revenue Growth	FY 2025	(3.0)% to (1.0)%	(2.5)% to (1.5)%	+0.5pts at both ends	Raised
GAAP EPS	FY 2025	$4.25 – $4.65	$4.15 – $4.35	-$0.20 at low end, -$0.30 at high end	Lowered
DSA Organic Revenue Growth	FY 2025	low to mid single-digit rate decline	(2.5)% to (3.5)%	quantified more aggressively; widened to explicit -2.5% to -3.5%	Lowered
Consolidated Operating Margin	FY 2025	flat to 30 basis point decline	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: RMS Organic Revenue Growth (flat to slightly positive), Manufacturing Organic Revenue Growth (flat to slightly lower)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Research Models and Services	$0.213B	+7.9%
Discovery and Safety Assessment	$0.601B	-2.3%
Manufacturing Solutions	$0.191B	-3.1%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Non-GAAP Operating Margin	19.7%
RMS Non-GAAP Operating Margin	25.0%
DSA Non-GAAP Operating Margin	25.4%
Manufacturing Non-GAAP Operating Margin	26.7%
Organic Revenue Growth (RMS)	6.5%
Organic Revenue Growth (DSA)	-3.1%
Organic Revenue Growth (Manufacturing)	-5.1%
Organic Revenue Growth (Total)	-1.6%

Management tone

Q1 FY2025 defensive uncertainty → Q2 FY2025 "stabilized and gradual progress" → Q3 FY2025 "clear signs that client demand has stabilized" with explicit recovery language.

The most consequential tonal shift this quarter is that management moved from describing DSA as stabilized to describing the broader industry as potentially recovering. Last quarter the language was "DSA business is stabilized and beginning to show signs of gradual progress"; this quarter is more affirmative: "we are continuing to see clear signs that client demand has stabilized…the industry may be on a path towards recovery." Paired with the disclosure that October was the second-highest month in biotech funding history and proposal activity up high single-digit, the framing is meaningfully more constructive than 90 days ago — but management still refused to translate that into 2026 numbers.

A deliberate countermove emerged on 2026 commitments. Across Q2 FY2025 management said it had "not factored in further demand improvements this year"; this quarter the deferral hardened: "It's still too early to provide even a preliminary outlook because we are still fully engaged in the budgeting process." Three of the five highest-significance Q&A exchanges (Donnelly, Caldwell, Woodring) tried to pin down 2026 DSA growth and were each turned away. This is unusual restraint from a management team simultaneously signaling recovery — and the contrast suggests either lower conviction than the prepared remarks imply, or an effort to keep sandbag room ahead of a strategic review payoff.

Portfolio framing has decisively shifted from optimization to repositioning. Last quarter the strategic review was characterized as "well underway" with no interim updates; this quarter management quantified outputs: 7% of revenue divesting and $225M+ in cumulative annualized savings. The phrasing "Once completed, the proposed divestitures are expected to result in non-GAAP earnings accretion of at least 30 cents per share on an annualized basis" reframes the review from cost defense to active value extraction. The strategic review is producing — not deliberating.

Manufacturing tone softened in a way that's easy to miss. The Q2 FY2025 language was "essentially flat"; this quarter is "flat to slightly lower… CDMO business, as well as biologics testing, are also driving a slightly less favorable outlook." Combined with the -5.1% organic Q3 FY2025 print and -3.1% reported revenue, the segment is the one place where the prior-quarter outlook was demonstrably too optimistic, and management absorbed it quietly inside an otherwise constructive call.

NAMs framing was elevated from adjacency to strategic core capability, with the announcement of FDA advisory leadership and a portfolio of integrated NAM examples. However, Anderson's Q&A drew out that NAMs adoption remains slow and unlikely to materially impact safety work near-term (positive for the existing book of business, but somewhat at odds with the strategic prominence given the topic in prepared remarks).

Recurring themes management leaned on this quarter:

Biotech funding environment stabilization and recovery signsDSA demand stabilization with cautious optimism for 2026 reboundPortfolio refinement and divestiture of 7% non-core revenueSubstantial cost savings ($225M+ annualized) and efficiency initiativesNAMs (new approach methodologies) as strategic growth avenue with regulatory positioningManufacturing headwinds from CDMO client losses but microbial solutions strength

Risks management surfaced:

Uncertainty remains in end markets despite stabilization signalsSmall and mid-sized biotech clients facing tighter budgets and funding constraintsDSA backlog decline from $1.93B to $1.80B signals potential revenue pressureBiologics testing experiencing lower sample volumes from biopharma and CDMO clients with project delaysFourth quarter DSA margin pressure from higher staffing costs and NHP sourcing expenses

Q&A highlights

Patrick Donnelly · Citi

What are you seeing from customers regarding biotech market loosening and demand trends given back-to-back quarters of low 0.8 book-to-bill? Is there a path to DSA growing in 2026 and what does that mean for margins?

Management sees proposals up, cancellations declining, and net bookings improving for pharma and biotech. Biotech funding was very strong in Q3 and October (second highest month in history). Book-to-bill improved over last 3-4 months. For 2026 growth, need to see sustained improvement in bookings, understand backlog dynamics, and assess study mix (short vs. long-term). Cannot commit to specific 2026 numbers yet.

Biotech funding up significantly in Q3; October was second highest month in biotech funding historyBook-to-bill improved for last 3-4 months sequentiallyBacklog at 9 months (vs. historical 6-9 months range)Pharma companies finished reducing portfolios

Dave Windley · Jefferies

Are you seeing more short-term versus long-term work in bookings? Are competitors experiencing study start timing issues that could impact your revenue conversion?

Beginning to see more short-term/pre-IND work, which signals client comfort with spending and improved capital access. Have flexibility to start studies quickly and with shorter backlog (9 months), can slot in studies when others slip. Unlike competitors, not experiencing study start timing delays; have capacity and ability to accommodate client timelines.

Backlog improved from 6-9 months range to 9 months with shorter average study durationAbility to start studies quickly with available capacityCompetitors experiencing study start timing delays that management is not facingShort-term work indicates client confidence to spend earlier in development process

Elizabeth Anderson · Evercore ISI

Are you seeing any change in behavior among client groups regarding NAMs adoption? Can you provide details on the $70 million incremental cost savings identified and their pacing?

NAMs adoption slow; most technologies still nascent and crude, providing anecdotal early-stage data mainly beneficial for discovery phase. Clients hearing FDA/regulatory focus on alternatives but scientific reality limits impact. Have assembled scientific advisory board and portfolio of NAM technologies for future positioning. $70M incremental savings from: facility consolidation, workforce right-sizing, procurement savings, GVS program improvements, and internal automation. Approximately $100M total incremental savings in 2026, but won't all flow to bottom line—will offset inflationary and cost pressures.

NAMs unlikely to materially impact safety work except for monoclonal antibodiesClients expected to file NAM data and animal data simultaneously going forwardCost savings categories: facility consolidation, workforce right-sizing, procurement, GVS program, automation$70 million incremental cost savings identified

Eric Caldwell · Baird

How much of the $100M incremental 2026 savings will fall to the bottom line? Given the backdrop of low 0.8 book-to-bills, is DSA headed for a down year in 2026?

Cannot specify bottom-line contribution yet—in middle of planning process. Intent is to use savings to expand earnings growth, but allocation between bottom-line flow and offset of headwinds not determined. On DSA 2026: management 'guardedly optimistic' but cannot predict actual numbers. Everything causing DSA decline over last 18 months was biotech access to capital; if biotech funding factors remain positive, will be beneficial. Needs continued improvement through Q4 and Q1 and client budget finalization.

Cannot quantify bottom-line benefit from cost savings at this timeFocused on reinvigorating earnings growth in 2026Guardedly optimistic on DSA if biotech funding factors remain positiveWaiting to see Q4 results and client budget finalization before making 2026 commitments

Casey Woodring · J.P. Morgan

Can you elaborate on higher third-party NHP sourcing costs in Q4 DSA margins and if this will be a drag in 2026? Can you quantify month-to-month book-to-bill progression (September vs. October) and exit year at >1.0?

Third-party NHP costs occur when demand exceeds internal capacity; higher sourcing costs are temporary procurement costs, not expected to be drag in 2026 if demand remains consistent and allows planning. Will not provide specific monthly book-to-bill data; prefers to look at trend over time. Book-to-bill has improved over last 3-4 months; cautiously optimistic trend continues but won't specify monthly breakout or Q4 target.

Higher third-party NHP costs due to exceeding internal capacity expectationsExpected demand levels in 2026 should not produce continuing drag from outsourcingBook-to-bill improved sequentially over past 3-4 monthsDeclining to disclose monthly book-to-bill specifics

Answers to last quarter's watch list

DSA net book-to-bill reversal above 0.90x in Q3 FY2025 — Management disclosed Q3 FY2025 net book-to-bill of 0.82x, identical to Q2 FY2025's 0.82x. Proposal activity was up high single-digit YoY and QoQ, and book-to-bill has improved sequentially for the last 3–4 months. The flat 0.82x print combined with the declining to commit to a >1.0x year-end exit suggests bookings are directionally improving but still well below the 0.90x threshold. Status: Resolved negatively on the headline ratio; directionally improving.

DSA H2 margin above 25% — DSA non-GAAP operating margin printed 25.4% in Q3 FY2025, narrowly clearing the 25% threshold. Q4 FY2025 will face additional pressure from higher staffing and third-party NHP sourcing costs, with non-GAAP EPS guided flat-to-down 10% sequentially. Status: Resolved positively for Q3 FY2025; at risk in Q4 FY2025.

Strategic review outcome — The review has produced concrete outputs: ~7% of FY2025 revenue identified for divestiture, $225M+ cumulative annualized cost savings, and $0.30+ EPS accretion expected from divestitures on completion. Not a full strategic conclusion (no take-private, no transformational restructuring), but a quantified portfolio repositioning rather than further deferral.

Resolved positively

2026 policy headwind quantification — Management did not provide any dollar framing for MSN pricing, tariffs, or NIH funding impact on 2026 on this call. The 2026 commentary was deferred wholesale to the next quarter pending budget finalization.

Not resolved

Manufacturing organic growth above 5% in Q3 FY2025 ex-CDMO — Manufacturing organic revenue declined -5.1%, well short of the +5% threshold, and the FY guide was quietly trimmed from "essentially flat" to "flat to slightly lower" due to CDMO and biologics testing weakness. The cleaner ex-headwind H2 thesis from last quarter did not hold.

Resolved negatively

What to watch into next quarter

Q4 FY2025 DSA book-to-bill exiting above 1.0x: management declined to commit to this on the call, but it is the cleanest gating signal for whether 2026 DSA growth is possible. Sustained sub-1.0x bookings while announcing 2026 guidance in February would force a downward revision.

2026 preliminary outlook on the Q4 FY2025 call: management deferred 2026 guidance pending Q4 FY2025 and early Q1 FY2026 bookings. Watch whether the Q4 FY2025 release contains a preliminary 2026 framing or further deferral — the latter would signal that the "stabilization" framing was less robust than implied.

Q4 FY2025 non-GAAP EPS landing point in the $2.19–$2.43 range: a Q4 FY2025 print near the low end implies DSA margin pressure is sharper than telegraphed; a print near $2.43 validates the "stabilization with margin protection" narrative.

Divestiture transaction announcement and timing: the 7% revenue divestiture and $0.30+ EPS accretion remain "expected" but not transacted. Watch for definitive transaction announcements; absence by Q1 FY2026 would suggest execution friction.

Manufacturing organic growth trajectory: -5.1% in Q3 FY2025 is the worst segment print and the only place where prior-quarter guidance was demonstrably wrong. Watch for whether Q4 FY2025 prints above -3% organic, which would suggest CDMO/biologics weakness is stabilizing rather than deepening.

Sources

Charles River Laboratories Q3 FY2025 earnings press release, filed 2025-11-05. https://www.sec.gov/Archives/edgar/data/1100682/000110068225000041/crl3q25earningsrelease.htm
Charles River Laboratories Q3 FY2025 earnings conference call (prepared remarks and Q&A).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.